{
    "clinical_study": {
        "@rank": "60354", 
        "arm_group": [
            {
                "arm_group_label": "prolonged ECG monitoring", 
                "arm_group_type": "Experimental", 
                "description": "Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6"
            }, 
            {
                "arm_group_label": "standard care", 
                "arm_group_type": "Other", 
                "description": "Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether repeated enhanced and prolonged ECG\n      monitoring after ischemic stroke results in a higher detection of atrial fibrillation\n      (/flutter) compared to usual care (at least 24 hour of cardiac monitoring)."
        }, 
        "brief_title": "Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting >\n             24h consistent with the territory of a major cerebral artery and categorised as\n             ischemic) and/or a corresponding lesion on brain imaging.\n\n          -  Stroke symptoms started \u2264 7 days ago.\n\n          -  Age \u2265 60 years.\n\n          -  Modified Rankin scale \u2264 2 (prior to index event).\n\n        Exclusion Criteria:\n\n          -  Known history of atrial fibrillation/flutter or atrial fibrillation/flutter on\n             admission ECG.\n\n          -  Indication for oral anticoagulation at randomisation.\n\n          -  Absolute contra-indication against oral anticoagulation at randomisation.\n\n          -  Intracerebral bleeding in medical history.\n\n          -  Patient scheduled for Holter-ECG or cardiac Event-Recording monitoring \u2265 48 hours.\n\n          -  Significant carotid artery or vertebral artery stenosis > 50% (NASCET\n             classification), significant intracranial artery stenosis suspicious of\n             atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\n\n          -  Implanted pacemaker device or cardioverter/defibrillator.\n\n          -  Life expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\n\n          -  Concomitant participation in other controlled randomised trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855035", 
            "org_study_id": "Find-AF randomised"
        }, 
        "intervention": [
            {
                "arm_group_label": "prolonged ECG monitoring", 
                "description": "10-day Holter ECG measurement", 
                "intervention_name": "prolonged ECG monitoring", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "standard care", 
                "description": "Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).", 
                "intervention_name": "standard care", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ischemic stroke", 
            "ECG monitoring", 
            "atrial fibrillation (/flutter)"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": [
            {
                "contact": {
                    "email": "wachter@med.uni-goettingen.de", 
                    "last_name": "Wachter, PD Dr. med.", 
                    "phone": "+49-551-39-9258"
                }, 
                "facility": {
                    "address": {
                        "city": "Goettingen", 
                        "country": "Germany", 
                        "zip": "37075"
                    }, 
                    "name": "Dept. of Cardiology and Pneumology, University Medical Center Goettingen"
                }, 
                "investigator": [
                    {
                        "last_name": "Rolf Wachter, PD Dr. med.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jan Liman, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Katrin Wasser, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Janin Wohlfahrt", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mark Weber-Kr\u00fcger", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Klaus.groeschel@unimedizin-mainz.de", 
                    "last_name": "Klaus Gr\u00f6schel, PD Dr. med.", 
                    "phone": "+49-6131-173105"
                }, 
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Clinic and Policlinic for Neurology, University of Mainz"
                }, 
                "investigator": [
                    {
                        "last_name": "Klaus Gr\u00f6schel, PD Dr. med.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Anne Grings", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "p.kermer@sanderbusch.de", 
                    "last_name": "Pawel Kermer, Prof. Dr. med.", 
                    "phone": "+49-4422-801401"
                }, 
                "facility": {
                    "address": {
                        "city": "Sande", 
                        "country": "Germany", 
                        "zip": "26452"
                    }, 
                    "name": "Dept. of Neurology, Nordwest-Hospital Sanderbusch"
                }, 
                "investigator": [
                    {
                        "last_name": "Pawel Kermer, Prof. Dr. med.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Evgeny Protsenko", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gerhard.hamann@hsk-wiesbaden.de", 
                    "last_name": "Gerhard Hamann, Prof. Dr. med.", 
                    "phone": "+49-611-43-2376"
                }, 
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany", 
                        "zip": "65199"
                    }, 
                    "name": "Dept. of Neurology, HSK, Dr. Horst-Schmidt-Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Gerhard Hamann, Prof. Dr. med.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Michaela Wagner-Heck, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jugoslav Erceg", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Joachim H\u00fcwel, Dr.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sven Klimpe, Dr.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomised, Controlled Study to Determine the Detection of Atrial Fibrillation by Prolonged and Enhanced Holter Monitoring as Compared to Usual Care in Stroke Patients", 
        "overall_official": [
            {
                "affiliation": "Dept. of Cardiology and Pneumology, University Medical Center Goettingen", 
                "last_name": "Rolf Wachter, PD Dr. med.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinic and Policlinic for Neurology, University of Mainz", 
                "last_name": "Klaus Gr\u00f6schel, PD Dr.med.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.", 
            "measure": "number of atrial fibrillation/flutter", 
            "safety_issue": "No", 
            "time_frame": "30 month after study start"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855035"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Detection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.", 
                "measure": "number of atrial fibrillation (/flutter) within 12 months after patient's inclusion", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "description": "Detection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.", 
                "measure": "number of atrial fibrillation (/flutter) without hospitalisation", 
                "safety_issue": "No", 
                "time_frame": "30 months after study start"
            }, 
            {
                "description": "Recurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.", 
                "measure": "number of recurrent stroke or systemic embolism", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "description": "Total death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.", 
                "measure": "total mortality", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "number of cardiovascular deaths", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "number of cerebrovascular deaths", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "number of transient ischemic attacks", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "number of myocardial infarctions", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "number of bleeding complications", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "description": "Incremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.", 
                "measure": "number of atrial fibrillation (/flutter) in extended monitoring period", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "measure": "costs", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }, 
            {
                "description": "To assess the feasibility of monitoring procedures.", 
                "measure": "number of correct monitorings", 
                "safety_issue": "No", 
                "time_frame": "24 months after study start"
            }
        ], 
        "source": "Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}